Lenz & Staehelin advised private equity healthcare specialist Archimed on its acquisition of a majority stake in family-owned ExcellGene and sister company Magellan Biologics & Consulting, both active in the biologic therapeutics sector. The deal
Homburger advised 21Shares on the listing of three new series of crypto-linked exchange ETPs as well as the cross-listing of three existing series of crypto-linked ETPs – all on the SIX Swiss Exchange. The series Amognst
Homburger advised Luzerner Kantonalbank on the issuance of CHF 200m Tier 2 bonds, carrying a coupon of 1.400%. Luzerner Kantonalbank and UBS served as joint-lead managers on the transaction. The bonds are set to listing on the
MME advised Particip8 Ventures on its acquisition of a 50% stake in Suixtrade. Pursuant to the deal, William Giger joins the operational management of Suixtrade, which he will lead together with Marcel Bangerter. Fabian Bamert of
Lukas Rusch (pictured) is Advestra’s latest partnership addition. He will lead the firm newly established dispute resolution practice. Rusch moves from Pestalozzi, where he spent 15 years from 2010 onwards, progressing from junior associate to partner
Lenz & Staehelin advised Prof. Dr. Martin Janssen in connection with the sale of Ecofin Investment Consulting – a company founded by Janssen himslef – to the Vaudoise Group. The company Headquartered in Zurich, Ecofin Investment Consulting
As of October 1st 2025, Christine Hohl (pictured) is joining Wenger Plattner as head of the firm’s financing practice, after her tenure at Loyens & Loeff. Hohl’s work mainly concentrates on international and national
Walder Wyss advised Bobst Group throughout the issuance of CHF 200m senior unsecured bonds maturing in 2030 and with 2.05% coupon. The bonds in question are set to debut on the SIX Swiss Exchange. UBS, BNP Paribas,
Altenburger advised Ensemble Hospitalier de la Côte (EHC) – a healthcare network encompassing 36 medical centers throughout Switzerland – on its acquisition of Niedol Center, a Renens-based specialist in dialysis. The Altenburger team Partner Manuel Moor (corporate/
Landis+Gyr divested its EMEA business to private equity investor Aurelius, for an enterprise value of USD 215 m. The divestment encompasses five production sites across EMEA and involves a workforce of approximately 2,700 employees. In connection
